Of the 125 recipients for whom alloantibody
data were available, 46.2% had developed de novo post-transplant donor-specific alloantibodies, and 19.5% had had pre-existing and post-transplant alloantibodies.
The addition of rare or new alloantibody
formation to a hemolytic transfusion reaction, such as HS, can increase the complexity of treatment and may require specialized blood products.
Our results showed that the majority of SCD patients had a single alloantibody
rather than multiple alloantibodies.
The risk of alloantibody
production and transfusion reactions against antigens other than DEA 1 is not yet well defined  and there is no documented clinical evidence of a hemolytic reaction caused by DEA 1.2, 3, 5, and 7 in mismatched transfusions .
Platelet transfusion refractoriness associated with HPA-1a (PlA1) alloantibody
without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions.
Impact of alloantibody
strength in crossmatch negative DSA positive kidney transplantation.
Qualitative variables in this study such as gender blood group presence or absence of alloantibody
and autoantibodies were expressed in terms of frequencies and percentages and presented as frequency distribution tables.
Sachs et al., "Long-term outcome and alloantibody
production in a non-myeloablative region for induction of renal allograft tolerance," Transplantation, vol.
IT can also be caused occasionally by the presence of a donor origin autoantibody  or by the presence of a recipient-origin alloantibody
against a donor platelet alloantigen.
Further laboratory results (direct antiglobulin test and bilirubin) were assessed and reported for five babies whose maternal alloantibody
titre by IAT tube was less than 16, but equal to 16 by CAT.
Immunotoxicity testing showed that there was no treatment-induced alloantibody
formation or induction of autoimmunity.
Maternal anti-K is the second most common alloantibody
(anti-D is the first) and accounts for 10%45% of all patients with antibody-mediated severe hemolytic anemia (2).